Latest Breaking News On - Prnewswire citius pharmaceuticals inc - Page 5 : comparemela.com

Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial

CRANFORD, N.J., Aug. 10, 2023 /PRNewswire/ Citius Pharmaceuticals, Inc. ( Citius or the Company ) (Nasdaq: CTXR), a late-stage biopharmaceuti.

United statesGreg salsburgIlanit allenLeonard mazurSecurities exchangeCitius pharmaceuticals incCompany nasdaqExchange commissionUniversity of texas md anderson cancer centerInfectious diseases society of americaPrnewswire citius pharmaceuticals incChief executive officerLok phaseMino lok phaseInfectious diseases societyCitius pharmaceuticals

Citius Pharmaceuticals, Inc Receives a Complete Response Letter from the U S Food and Drug Administration (FDA) for LYMPHIR™ (Denileukin Diftitox) for the Treatment of Patients with Relapsed or Refractory Cutaneous T-Cell Lymphoma

No clinical efficacy or safety issues raised Citius committed to working toward approval CRANFORD, N.J., July 29, 2023 /PRNewswire/ Citius Pharmaceuticals, Inc. today announced that the U.S..

Ilanit allenLeonard mazurGreg salsburgCompany biologics license applicationSecurities exchangeExchange commissionCitius pharmaceuticals incCompany nasdaqPrnewswire citius pharmaceuticals incDrug administrationComplete response letterBiologics license applicationCitius pharmaceuticalsFast trackSecurities actSecurities exchange act

Citius Pharmaceuticals Announces Positive Results from the Phase 2b Study of Halo-Lido (CITI-002) for the Treatment of Hemorrhoids

CITI-002 provides a meaningful reduction in symptom severity when compared to individual components alone Dose for Phase 3 trial selected; Citius to schedule end of Phase 2 meeting with the. | June 20, 2023

Ilanit allenLeonard mazurMyron czuczmanGreg salsburgCitius pharmaceuticals incCompany phaseSecurities exchangeExchange commissionPrnewswire citius pharmaceuticals incDrug administrationPatient reported outcomeHalo lido phaseCentury cures actHemorrhoid qualityLife indexTrial results

Citius Pharmaceuticals to Participate in Maxim Group s Virtual Healthcare Conference on June 21, 2023

/PRNewswire/ Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development.

Leonard mazurMichael okunewitchIlanit allenPrnewswire citius pharmaceuticals incMaxim group virtual healthcare conference onCompany nasdaqCitius pharmaceuticals incSenior biotech research analystMaxim groupVirtual healthcare conferenceCitius pharmaceuticalsFast trackHealth care amp hospitalsMedical pharmaceuticalsTrade show news

Citius Pharmaceuticals, Inc Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update

Citius Pharmaceuticals, Inc Reports Fiscal Second Quarter 2023 Financial Results and Provides Business Update
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

New jerseyUnited statesIlanit allenGreg salsburgLeonard mazurExchange commissionCompany nasdaqCitius pharmaceuticals incPrnewswire citius pharmaceuticals incSecurities exchangeDevelopment rd expensesJersey technology business tax certificate transfer programLido phaseHalo lido phaseMino lok phaseCitius pharmaceuticals